19 results on '"Zhang, Ju"'
Search Results
2. Kinesin family member 11 promotes progression of hepatocellular carcinoma via the OCT4 pathway
- Author
-
Zhang, Ju, Wei, Zuxing, Qi, Xiaoyan, Jiang, Yuhong, Liu, Dekun, and Liu, Kuijie
- Published
- 2023
- Full Text
- View/download PDF
3. Cirrhotic-extracellular matrix attenuates aPD-1 treatment response by initiating immunosuppressive neutrophil extracellular traps formation in hepatocellular carcinoma.
- Author
-
Shen, Xiao-Tian, Xie, Sun-Zhe, Zheng, Xin, Zou, Tian-Tian, Hu, Bei-Yuan, Xu, Jing, Liu, Lu, Xu, Yun-Feng, Wang, Xu-Feng, Wang, Hao, Wang, Shun, Zhu, Le, Yu, Kang-Kang, Zhu, Wen-Wei, Lu, Lu, Zhang, Ju-Bo, Chen, Jin-Hong, Dong, Qiong-Zhu, Yang, Lu-Yu, and Qin, Lun-Xiu
- Subjects
HEPATOCELLULAR carcinoma ,NEUTROPHILS ,EXTRACELLULAR matrix ,IMMUNE checkpoint inhibitors ,CELL physiology - Abstract
Background: Hepatocellular carcinoma (HCC) is closely associatedwith chronic liver diseases, particularly liver cirrhosis, which has an altered extracellular matrix (ECM) composition. The influence and its mechanism of the cirrhotic-ECM on the response of HCC to immune checkpoint inhibitor (ICI) remains less clarified. Methods: In silico, proteomic and pathological assessment of alteration of cirrhotic-ECM were applied in clinical cohort. Multiple pre-clinical models with ECM manipulation were used to evaluate cirrhotic-ECM's effect on ICI treatment. In silico, flow cytometry and IHC were applied to explore how cirrhotic-ECM affect HCC microenvironment. In vitro and in vivo experiments were carried out to identify the mechanism of how cirrhotic-ECM undermined ICI treatment. Results: We defined "a pro-tumor cirrhotic-ECM" which was featured as the up-regulation of collagen type 1 (Col1). Cirrhotic-ECM/Col1 was closely related to impaired T cell function and limited anti PD-1 (aPD-1) response of HCC patients from the TCGA pan cancer cohort and the authors' institution, as well as in multiple pre-clinical models. Mechanically, cirrhotic-ECM/Col1 orchestrated an immunosuppressive microenvironment (TME) by triggering Col1-DDR1-NFκB-CXCL8 axis, which initiated neutrophil extracellular traps (NETs) formation to shield HCC cells from attacking T cells and impede approaching T cells. Nilotinib, an inhibitor of DDR1, reversed the neutrophils/NETs dominant TME and efficiently enhanced the response of HCC to aPD-1. Conclusions: Cirrhotic-ECM modulated a NETs enriched TME in HCC, produced an immune suppressive TME and weakened ICI efficiency. Col1 receptor DDR1 could be a potential target synergically used with ICI to overcome ECM mediated ICI resistance. These provide a mechanical insight and novel strategy to overcome the ICI resistance of HCC. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. LncRNA MYLK-AS1 facilitates tumor progression and angiogenesis by targeting miR-424-5p/E2F7 axis and activating VEGFR-2 signaling pathway in hepatocellular carcinoma
- Author
-
Teng, Fei, Zhang, Ju-Xiang, Chang, Qi-Meng, Wu, Xu-Bo, Tang, Wei-Guo, Wang, Jian-Fa, Feng, Jin-Feng, Zhang, Zi-Ping, and Hu, Zhi-Qiu
- Published
- 2020
- Full Text
- View/download PDF
5. Long-term outcomes and prognostic analysis of radiofrequency ablation for small hepatocellular carcinoma: 10-year follow-up in Chinese patients
- Author
-
Zhang, Lan, Ge, Ning-Lin, Chen, Yi, Xie, Xiao-Ying, Yin, Xin, Gan, Yu-Hong, Zhang, Bo-Heng, Zhang, Ju-Bo, Chen, Rong-Xin, Wang, Yan-Hong, Ye, Sheng-Long, and Ren, Zheng-Gang
- Published
- 2015
- Full Text
- View/download PDF
6. A novel tripeptide, tyroserleutide, inhibits irradiation-induced invasiveness and metastasis of hepatocellular carcinoma in nude mice
- Author
-
Jia, Jin-Bin, Wang, Wen-Quan, Sun, Hui-Chuan, Liu, Liang, Zhu, Xiao-Dong, Kong, Ling-Qun, Chai, Zong-Tao, Zhang, Wei, Zhang, Ju-Bo, Xu, Hua-Xiang, Zeng, Zhao-Chong, Wu, Wei-Zhong, Wang, Lu, and Tang, Zhao-You
- Published
- 2011
- Full Text
- View/download PDF
7. Bevacizumab enhances chemosensitivity of hepatocellular carcinoma to adriamycin related to inhibition of survivin expression
- Author
-
Xiong, Yu-Quan, Sun, Hui-Chuan, Zhu, Xiao-Dong, Zhang, Wei, Zhuang, Peng-Yuan, Zhang, Ju-Bo, Xu, Hua-Xiang, Kong, Ling-Qun, Wu, Wei-Zhong, Qin, Lun-Xiu, and Tang, Zhao-You
- Published
- 2011
- Full Text
- View/download PDF
8. Protein expression profiling of vascular endothelial growth factor and its receptors identifies subclasses of hepatocellular carcinoma and predicts survival
- Author
-
Jia, Jin-Bin, Zhuang, Peng-Yuan, Sun, Hui-Chuan, Zhang, Ju-Bo, Zhang, Wei, Zhu, Xiao-Dong, Xiong, Yu-Quan, Xu, Hua-Xiang, and Tang, Zhao-You
- Published
- 2009
- Full Text
- View/download PDF
9. Up-regulation of platelet-derived growth factor-A is responsible for the failure of re-initiated interferon alpha treatment in hepatocellular carcinoma
- Author
-
Zhang Ju-Bo, Sun Hui-Chuan, Jia Wei-Dong, Zhuang Peng-Yuan, Qian Yong-Bing, Zhu Xiao-Dong, Kong Ling-Qun, Wang Lu, Wu Wei-Zhong, and Tang Zhao-You
- Subjects
Hepatocellular carcinoma ,Interferon-α ,Platelet-derived growth factor-A ,Vascular endothelial growth factor ,Microvessel density ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Postoperative interferon-α(IFN-α) treatment delays hepatocellular carcinoma(HCC) recurrence and prolongs patient survival, and may thus be an effective form of adjuvant therapy. However, clinical observations found that HCC recurs in some patients within 8 months of IFN-α treatment being discontinued. We investigated whether HCC regrowth appears after IFN-α is discontinued, whether re-initiated IFN-α is effective, and the underlying mechanisms of IFN-α treatment. Methods The human HCC nude mouse model LCI-D20 was used to study the effects of IFN-α treatment, discontinued IFN-α treatment, and re-initiated IFN-α treatment on tumor growth. Tumor weight, microvessel density(MVD), serum vascular endothelial growth factor (VEGF), and tumor cell apoptosis were analyzed. Angiogenesis-related factors were studied using cDNA microarray in different tumor samples and confirmed using reverse transcription–polymerase chain reaction(RT-PCR) and Western blotting assays. Finally, imatinib was added with re-initiated IFN-α treatment to improve efficacy. Results IFN-α (1.5×107 U/kg/day for 20 days) suppressed HCC growth by 60.3% and decreased MVD by 52.2% compared with the control. However, tumor regrowth occurred after IFN-α was discontinued, and re-initiated IFN-α treatment was not effective for inhibiting tumor growth or reducing MVD compared with a saline-treated group. cDNA microarray showed VEGF was down-regulated while platelet-derived growth factor-A (PDGF-A) was up-regulated when IFN-α treatment was re-initiated. These findings were further confirmed with RT-PCR and Western blotting assay. The combination of imatinib with re-initiated IFN-α reduced HCC weight by 30.7% and decreased MVD by 31.1% compared with IFN-α treatment only (P=0.003 and 0.015, respectively). Conclusion Tumor regrowth occurred after IFN-α treatment was discontinued. Re-initiated IFN-α treatment was not effective and was associated with up-regulation of PDGF-A, while the VEGF remained suppressed. The combination of a PDGF-receptor inhibitor with IFN-α improved the effect of the re-initiated treatment.
- Published
- 2012
- Full Text
- View/download PDF
10. Detection of HBV Genotypes of Tumor Tissues and Serum by A Fluorescence Polarization Assay in North-Western China's Hepatocellular Carcinoma Patients
- Author
-
Liang Ping, Wang Xiangling, Li Ding, Cheng Hong, Wu Zhiqun, Gong Weidong, Lu Jianguo, and Zhang Ju
- Subjects
hepatitis B virus genotype ,hepatocellular carcinoma ,fluorescence polarization ,north-western China ,Infectious and parasitic diseases ,RC109-216 - Abstract
Abstract Background The understanding of the distribution of hepatitis B virus genotypes and the occult hepatitis B virus infection in hepatocellular carcinoma may shed light into the prevention and treatment of hepatocellular carcinoma. The purpose of the study is to investigate hepatitis B virus genotypes distribution, the high-risk genotypes and the occult infection in north-western China's hepatocellular carcinoma patients. Methods Hepatitis B virus genotypes A-D of hepatocellular carcinoma tumor tissues and serum samples in 268 north-western China hepatocellular carcinoma patients were detected by fluorescence polarization assay. The hepatitis B virus genotypes in serum and matched primary tumor tissue samples were compared. Hepatitis B surface antigen and α-fetoprotein in serum were detected. Occult hepatitis B virus infections were analyzed. The relationship between hepatitis B virus genotypes and clinicopathologic characteristics were analyzed statistically using SPSS v.10.0. Results Intrahepatic hepatitis B virus DNA was detected in 83.6% of 268 patients, whereas serum hepatitis B virus DNA was detected in 78.7%. The hepatitis B virus genotypes in serum were consistent with the results in matched tumor tissue. Intrahepatic hepatitis B virus genotype B and C were detected respectively in 11.6% and 54.5% of the patients. Mixed intrahepatic hepatitis B virus genotypes were detected in 13.4% of 268 patients. There was not mixed hepatitis B virus infection in Edmondonson grade I. The patients with mixed HBV genotypes exhibited statistically significant different Edmondson grade than the patients with single type HBV infection (p < 0.05). Hepatitis B surface antigens were positive in 77.2% of 268 patients. Hepatitis B virus genotype C was detected in 64.7% of occult infected patients. There was no significant differences of patients' ages and α-fetoprotein level in different groups of intrahepatic hepatitis B virus genotypes (p > 0.05). Conclusions Hepatitis B virus genotype C was associated closely with the development of hepatocellular carcinoma and the occult hepatitis B virus infection in patients in north-western China. There was a relatively high prevalence of mixed hepatitis B virus infection in Edmondonson grade III-IV.
- Published
- 2011
- Full Text
- View/download PDF
11. Correction to: LncRNA MYLK-AS1 facilitates tumor progression and angiogenesis by targeting miR-424-5p/E2F7 axis and activating VEGFR-2 signaling pathway in hepatocellular carcinoma.
- Author
-
Teng, Fei, Zhang, Ju-Xiang, Chang, Qi-Meng, Wu, Xu-Bo, Tang, Wei-Guo, Wang, Jian-Fa, Feng, Jin-Feng, Zhang, Zi-Ping, and Hu, Zhi-Qiu
- Subjects
- *
LINCRNA , *HEPATOCELLULAR carcinoma , *CANCER invasiveness , *NEOVASCULARIZATION - Abstract
An amendment to this paper has been published and can be accessed via the original article. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
12. The Prognostic Comparison Between Hepatocellular Carcinoma with Portal Vein Tumor Thrombus and Bile Duct Cancer Thrombus After Liver Resection.
- Author
-
Yang, Xin, Zhu, Ying, Zhao, Xia, Li, Jian-hua, Xu, Da, Jia, Hu-Liang, and Zhang, Ju-bo
- Subjects
BILIARY tract cancer ,PORTAL vein ,HEPATOCELLULAR carcinoma ,THROMBOSIS ,LYMPHATIC metastasis - Abstract
Background and Objective: Hepatocellular carcinoma (HCC) often invades the portal vein and its branches to form portal vein tumor thrombus (PVTT), and it rarely spreads into the bile ducts to cause bile duct tumor thrombus (BDTT). However, the clinical prognosis of patients with the two types of tumor thrombus is different. In this manuscript, we plan to compare the prognosis of HCC with PVTT and BDTT for further clinical treatment. Patients and Methods: A total of 60 patients including 48 HCC cases with PVTT and 12 HCC cases with BDTT were enrolled in the study. The medical records were collected from participants. The follow-up was performed in 3 years post-hepatectomy. Statistical analysis was performed to explore the relationship between tumor thrombus with clinicopathological characteristics, to determine the significant preoperative factors influencing overall survival (OS) and time to recurrence (TTR), and to establish the survival and recurrent curves. Results: HCC with BDTT or PVTT often combined with viral hepatitis B, accompanied by varying degrees of cirrhosis, and high AFP level (68.3%), complete tumor capsule (76.7%), and larger tumor size (85.0%). Furtherly, patients with HCC and BDTT tended to have higher total bilirubin (TB) and more possibility of lymph node metastases. The multivariate Cox hazard analyses also revealed that both tumor size and tumor thrombus could be taken as independent prognostic indicators of HCC patients. Survival curves showed that the 1-, 2- and 3-year OS or DFS rates of HCC patients with BDTT were significantly lower than those of HCC patients with PVTT, respectively. Conclusion: Tumor thrombus is an independent risk factor for poor survival and high recurrence in HCC. HCC patients with BDTT had shorter overall survival and higher tumor recurrence rate compared to HCC patients with PVTT. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
13. Increased neutrophil extracellular traps promote metastasis potential of hepatocellular carcinoma via provoking tumorous inflammatory response.
- Author
-
Yang, Lu-Yu, Luo, Qin, Lu, Lu, Zhu, Wen-Wei, Sun, Hao-Ting, Wei, Ran, Lin, Zhi-Fei, Wang, Xiang-Yu, Wang, Chao-Qun, Lu, Ming, Jia, Hu-Liang, Chen, Jin-Hong, Zhang, Ju-Bo, and Qin, Lun-Xiu
- Subjects
HEPATOCELLULAR carcinoma ,METASTASIS ,TOLL-like receptors ,NEUTROPHILS - Abstract
Background: The propensity of the activated neutrophils to form extracellular traps (NETs) is demonstrated in multiple inflammatory conditions. In this study, we investigated the roles of NETs in metastasis of hepatocellular carcinoma (HCC) and further explored the underlying mechanism of how NETs affect metastasis as well as the therapeutic value. Methods: The neutrophils were isolated from the blood of human HCC patients and used to evaluate the formation of NETs. The expression of NET markers was detected in tumor specimens. A LPS-induced NET model was used to investigate the role of NETs on HCC metastasis. RNA-seq was performed to identify the key molecular event triggered by NETs, and their underlying mechanism and therapeutic significance were explored using both in vitro and in vivo assays. Results: NET formation was enhanced in neutrophils derived from HCC patients, especially those with metastatic HCCs. NETs trapped HCC cells and subsequently induced cell-death resistance and enhanced invasiveness to trigger their metastatic potential, which was mediated by internalization of NETs into trapped HCC cells and activation of Toll-like receptors TLR4/9-COX2 signaling. Inhibition of TLR4/9-COX2 signaling abrogated the NET-aroused metastatic potential. A combination of DNase 1 directly wrecking NETs with anti-inflammation drugs aspirin/hydroxychloroquine effectively reduced HCC metastasis in mice model. Conclusions: NETs trigger tumorous inflammatory response and fuel HCC metastasis. Targeting NETs rather than neutrophils themselves can be a practice strategy against HCC metastasis. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
14. Maintenance of Stemness in Oxaliplatin-Resistant Hepatocellular Carcinoma Is Associated with Increased Autocrine of IGF1.
- Author
-
Bu, Yang, Jia, Qing-An, Ren, Zheng-Gang, Zhang, Ju-Bo, Jiang, Xue-Mei, Liang, Lei, Xue, Tong-Chun, Zhang, Quan-Bao, Wang, Yan-Hong, Zhang, Lan, Xie, Xiao-Ying, and Tang, Zhao-You
- Subjects
OXALIPLATIN ,LIVER cancer ,AUTOCRINE mechanisms ,CANCER stem cells ,CANCER chemotherapy ,LABORATORY mice - Abstract
Background: Evidence suggests that many types of cancers are composed of different cell types, including cancer stem cells (CSCs). We have previously shown that the chemotherapeutic agent oxaliplatin induced epithelial-mesenchymal transition, which is thought to be an important mechanism for generating CSCs. In the present study, we investigate whether oxaliplatin-treated cancer tissues possess characteristics of CSCs, and explore oxaliplatin resistance in these tissues. Methods: Hepatocellular carcinoma cells (MHCC97H cells) were subcutaneously injected into mice to form tumors, and the mice were intravenously treated with either oxaliplatin or glucose. Five weeks later, the tumors were orthotopically xenografted into livers of other mice, and these mice were treated with either oxaliplatin or glucose. Metastatic potential, sensitivity to oxaliplatin, and expression of CSC-related markers in the xenografted tumor tissues were evaluated. DNA microarrays were used to measure changes in gene expression as a result of oxaliplatin treatment. Additionally, an oxaliplatin-resistant cell line (MHCC97H-OXA) was established to assess insulin-like growth factor 1 secretion, cell invasion, cell colony formation, oxaliplatin sensitivity, and expression of CSC-related markers. The effects of an insulin-like growth factor 1 receptor inhibitor were also assessed. Results: Oxaliplatin treatment inhibited subcutaneous tumor growth. Tumors from oxaliplatin-treated mice that were subsequently xenografted into livers of other mice exhibited that decreasing sensitivity to oxaliplatin and increasing pulmonary metastatic potential. Among the expression of CSC-related proteins, the gene for insulin-like growth factor 1, was up-regulated expecially in these tumor tissues. Additionally, MHCC97H-OXA cells demonstrated that increasing cell invasion, colony formation, and expression of insulin-like growth factor 1 and CSC-related markers, whereas treatment with an inhibitor of the insulin-like growth factor 1 receptor suppressed these effects. Conclusion: Maintenance of stemness in oxaliplatin-resistant hepatocellular carcinoma cells is associated with increased autocrine of IGF1. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
15. The Clinical Significance of the CD163+ and CD68+ Macrophages in Patients with Hepatocellular Carcinoma.
- Author
-
Kong, Ling-Qun, Zhu, Xiao-Dong, Xu, Hua-Xiang, Zhang, Ju-Bo, Lu, Lu, Wang, Wen-Quan, Zhang, Qiang-Bo, Wu, Wei-Zhong, Wang, Lu, Fan, Jia, Tang, Zhao-You, and Sun, Hui-Chuan
- Subjects
LIVER cancer ,MACROPHAGE activation ,T cells ,LIVER surgery ,FLOW cytometry ,CANCER relapse ,HEPATITIS ,PROGNOSIS - Abstract
Our previous study has found that the abundance of peritumoral CD68
+ macrophages was associated with poor prognosis in hepatocellular carcinoma (HCC) after resection. However, CD68 staining could not discriminate the protumoral or tumoricidal subpopulations from pan-macrophages. CD163 is a marker of alternatively activated macrophages. In this study, the clinical significance of CD163+ cells in tumors and peritumoral liver tissues was evaluated in a cohort of 295 patients with HCC after curative resection. We found that the density of CD163+ cells was well correlated with that of CD68+ cells in both tumors and peritumoral liver tissues but was much more. Immunostaining on consecutive sections and flow cytometry assay on surgical resected specimens further supported the findings that the CD163+ cells was more abundant than CD68+ cells. The density of peritumoral CD68+ cells was associated with poor recurrence-free survival (RFS) and poor overall survival (OS) (P = 0.004 and P = 0.001, respectively), whereas the CD163+ cells have no prognostic values either in tumors or in peritumoral liver tissues. In another cohort of 107 HCC patients, preoperative plasma concentration of soluble form of CD163 (sCD163) was associated with active hepatitis-related factors but not associated with the markers of tumor invasion. In conclusion, both the CD163+ cells local infiltration and plasma sCD163 were of limited significance in HCC, and they were more likely markers related to active hepatitis rather than tumor progression. [ABSTRACT FROM AUTHOR]- Published
- 2013
- Full Text
- View/download PDF
16. Direct Transformation of Lung Microenvironment by Interferon-α Treatment Counteracts Growth of Lung Metastasis of Hepatocellular Carcinoma.
- Author
-
Zhuang, Peng-Yuan, Shen, Jun, Zhu, Xiao-Dong, Zhang, Ju-Bo, Tang, Zhao-You, Qin, Lun-Xiu, and Sun, Hui-Chuan
- Subjects
LUNG cancer treatment ,LIVER cancer ,INTERFERONS ,METASTASIS ,TUMOR growth ,GENETIC transformation ,IMMUNOHISTOCHEMISTRY ,LABORATORY mice - Abstract
Background: Interferon (IFN)-α is effective in inhibiting tumor growth and metastasis of hepatocellular carcinoma (HCC). However, the biologic mechanisms of IFN-α treatment in lung metastasis are not yet clear. Methods: The effect of IFN-α treatment was studied by using an orthotopic xenograft model and measuring tumor size and lung metastasis. Pretreatment with IFN-α before implantation of tumor was done to explore the effect of IFN-α on lung tissues. Cytokines and macrophages were measured by immunohistochemistry and/or PCR assay, using human origin or mouse origin primers to differentiate the sources. Circulating tumor cells (CTCs) were also assayed by flow cytometry. Results: IFN-α treatment did not decrease the number of CTCs (0.075%±0.020% versus 0.063%±0.018%, P = 0.574, IFN-α–treated versus control groups), but did decrease the number and size of lung metastasis (number: 1.75±1.0 versus 28.0±6.3, P = 0.008; size [pixels]: 116.8±72.2 versus 5226.4±1355.7, P = 0.020), and inhibited macrophage infiltration (0.20%±0.04% versus 1.36%±0.21%, P = 0.0058) and alteration of matrix metalloproteinase (MMP)-9 expression (mean integrated optical density (IOD): 5.1±1.7 versus 21.9±0.4, P<0.000) in the lung, which was independent of the primary tumor. Conclusion: IFN-α inhibited lung metastasis by directly modulating the lung microenvironment. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
17. Clinical and bacteriological features and prognosis of ascitic fluid infection in Chinese patients with cirrhosis.
- Author
-
Ning, Nian-zhi, Li, Tao, Zhang, Ju-ling, Qu, Fen, Huang, Jie, Liu, Xiong, Li, Zhan, Geng, Wei, Fu, Jun-liang, Huan, Wang, Zhang, Shu-yong, Bao, Chun-mei, and Wang, Hui
- Subjects
CIRRHOSIS of the liver ,ASCITIC fluids ,INFECTION ,BACTERIOLOGY ,MORTALITY ,BLOOD urea nitrogen ,PATIENTS ,ASCITES ,BACTERIAL diseases ,BODY fluids ,DRUG resistance in microorganisms ,GRAM-negative bacteria ,HEPATOCELLULAR carcinoma ,LIVER tumors ,PERITONITIS ,PROGNOSIS ,RESEARCH funding ,RETROSPECTIVE studies ,DISEASE complications - Abstract
Background: Spontaneous bacterial peritonitis (SBP) and bacterascites (BA) represent frequent and serious complications in cirrhosis patients with ascites. However, few detailed data are available regarding the clinical and bacteriological feature of SBP or BA patients in China.Methods: We retrospectively analyzed bacteriological and clinical characteristics of patients with SBP and BA at Beijing 302 Hospital in China from January 2012 to December 2015.Results: A total of 600 patients with SBP (n = 408) or BA (n = 192) were enrolled. Patients with BA appeared to have a less severe clinical manifestation and lower mortality rate than patients with SBP. Gram-negative bacteria formed the majority of pathogens in SBP (73.9%) and BA (55.8%) cases. Higher ascitic fluid polymorphonuclear leucocytes (PMN) count and hepatocellular carcinoma were independent risk factors for BA episode progressing to SBP. The concentration of blood urea nitrogen (BUN) was independent risk factor for 30-day mortality of BA patients. For patients with SBP, the independent risk factors for 30-day mortality were age, Model for End-Stage Liver Disease (MELD) score, septic shock and hepatocellular carcinoma. Patients with third-generation cephalosporin or carbapenems resistant infection had a significantly lower survival probability. There were significant differences in clinical characteristics and outcome among the major bacteria. Multivariate analysis showed that patients infected with Klebsiella spp. had higher hazard ratio of 30-day mortality.Conclusion: Our study reported the bacteriological and clinical characteristics of patients with SBP and BA. Higher ascitic fluid PMN count and hepatocellular carcinoma were found to be independent risk factors for BA episode progressed to SBP. Outcome of ascitic fluid infection in patients with cirrhosis was influenced by the type of bacteria and antimicrobial susceptibility. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
18. Identification of two immune-related risk score signatures through integrated analysis of multi-omics data in hepatocellular carcinoma.
- Author
-
Fu, Jie, Cao, Zhenyu, Zhang, Ju, Chen, Qilin, Wang, Yu, Wang, Sixue, Fang, Xiaoling, and Xu, Xundi
- Subjects
- *
DISEASE risk factors , *HEPATOCELLULAR carcinoma , *DATA analysis , *DRUG target , *TREATMENT effectiveness , *NOMOGRAPHY (Mathematics) - Abstract
• Two risk scores (ICS and ICRGS) were constructed through integrated analysis of bulk and scRNA sequencing data in HCC. • The functional roles of the DEGs between the prognostic immune cells were clarified by enrichment analyses. • The interaction among the prognostic immune cells was preliminarily investigated by cell–cell communication analysis. • Potential therapeutic drugs targeting prognostic DEGs were screened by CellMiner. Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death worldwide. Immunotherapy has become a major treatment for advanced HCC, but the therapeutic effects remain unsatisfactory. In this study, we constructed an immune cell risk score (ICS) and an immune cell-related gene risk score (ICRGS) for the prognosis prediction of HCC through integrated analysis of bulk and single-cell RNA (scRNA) sequencing data. These two risk score signatures both showed good predictive values in the training and validation cohorts. The potential interactions among these prognostic immune cell types were elucidated by cell–cell communication analysis. The results of enrichment analysis and gene set enrichment analysis (GSEA) of the prognostic genes showed that metabolic-related processes were involved in the immune response of HCC. Furthermore, the results of correlation analyses further confirmed the hub genes that were strongly correlated with immune cells. Finally, potential therapeutic drugs targeting these hub genes were screened by CellMiner based on NCI-60 cell line set. Taken together, two useful models for the prognosis prediction of HCC patients were constructed in this study. The functional differences between the two groups of HCC patients separated by ICS or ICRGS provide fundamental knowledge for finding synergistic therapeutic targets for HCC immunotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
19. A novel peptide that selectively binds highly metastatic hepatocellular carcinoma cell surface is related to invasion and metastasis
- Author
-
Jia, Wei-Dong, Sun, Hui-Chuan, Zhang, Ju-Bo, Xu, Yang, Qian, Yong-Bing, Pang, Jin-Zhong, Wang, Lu, Qin, Lun-Xiu, Liu, Yin-Kun, and Tang, Zhao-You
- Subjects
- *
LIVER cancer , *PEPTIDES , *LIGAND binding (Biochemistry) , *METASTASIS - Abstract
Abstract: Using a phage display approach, we identified AWYPLPP peptide as a specific peptide ligand that binds to the cell surface of highly metastatic human hepatocellular carcinoma (HCC). Moreover, the peptide was able to promote in vitro invasion of highly metastatic HCC cells by activating matrix metalloproteinase-9 and in vivo lung metastasis of HCC tumors. These results indicate that AWYPLPP peptide likely recognizes a novel receptor that is selectively expressed on the cell surface of highly metastatic HCC and mediates cellular activities associated with the invasive phenotype. Identification of the receptor for the AWYPLPP peptide may provide new insights into the molecular mechanism of HCC metastasis. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.